Cargando…
CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives
Dendritic cell (DC)-based immunotherapies are being explored for over 20 years and found to be very safe. Most often, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4)-induced monocyte-derived DCs (moDCs) are being used, which have demonstrated some life-prolonging b...
Autores principales: | Zeng, Qun, Zhou, Yubin, Schwarz, Herbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783506/ https://www.ncbi.nlm.nih.gov/pubmed/31632390 http://dx.doi.org/10.3389/fimmu.2019.02216 |
Ejemplares similares
-
Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs
por: Zeng, Qun, et al.
Publicado: (2019) -
Identification of CD137-Expressing B Cells in Multiple Sclerosis Which Secrete IL-6 Upon Engagement by CD137 Ligand
por: Wong, Hiu Yi, et al.
Publicado: (2020) -
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
por: Luu, Khang, et al.
Publicado: (2021) -
The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus
por: Mak, Anselm, et al.
Publicado: (2019) -
Deletion of CD137 Ligand Exacerbates Renal and Cutaneous but Alleviates Cerebral Manifestations in Lupus
por: Mak, Anselm, et al.
Publicado: (2019)